BR112018016475A2 - derivados de tetrahidroisoquinolina - Google Patents

derivados de tetrahidroisoquinolina

Info

Publication number
BR112018016475A2
BR112018016475A2 BR112018016475A BR112018016475A BR112018016475A2 BR 112018016475 A2 BR112018016475 A2 BR 112018016475A2 BR 112018016475 A BR112018016475 A BR 112018016475A BR 112018016475 A BR112018016475 A BR 112018016475A BR 112018016475 A2 BR112018016475 A2 BR 112018016475A2
Authority
BR
Brazil
Prior art keywords
muscle
troponin
disorders
skeletal
pharmaceutical composition
Prior art date
Application number
BR112018016475A
Other languages
English (en)
Inventor
Paul Morgan Bradley
Malik Fady
Tanaka Hiroaki
Kiyohara Hiroshi
Sato Ippei
Michael Warrington Jeffrey
Mihara Kayoko
Ashcraft Luke
Garard Marc
Miura Masanori
Ohe Munemichi
Lu Pu-Ping
Emile Collibee Scott
Yamaki Susumu
Kamikubo Takashi
Saito Tomoyuki
Shiina Yasuhiro
Matsushima Yuji
Original Assignee
Astellas Pharma Inc
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Cytokinetics Inc filed Critical Astellas Pharma Inc
Publication of BR112018016475A2 publication Critical patent/BR112018016475A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C12N2509/10—Mechanical dissociation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

novos compostos derivados de tetrahidroisoquinolina são divulgados neste documento, os quais podem ser utilizados como um ingrediente ativo para uma composição farmacêutica e, em particular, para uma composição farmacêutica útil para prevenir ou tratar uma doença ou condição responsiva à modulação da contratilidade do sarcômero esquelético. isto pode ser conseguido, por exemplo, por meio da modulação do complexo troponina do sarcômero do músculo esquelético de contração rápida através de uma ou mais de miosina, actina, tropomiosina, troponina c, troponina i e troponina t esquelética de contração rápida, e fragmentos e isoformas das mesmas. os compostos derivados de tetrahidroisoquinolina podem, portanto, ser usados como um agente para prevenir ou tratar 1) distúrbios neuromusculares, 2) distúrbios de músculo voluntário, 3) distúrbios do snc, nos quais a fraqueza muscular, atrofia e fadiga são sintomas proeminentes, 4) sintomas musculares decorrentes de distúrbios sistêmicos e 5) disfunção do assoalho pélvico e do músculo do esfíncter uretral/anal.
BR112018016475A 2016-02-12 2017-02-10 derivados de tetrahidroisoquinolina BR112018016475A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662285039P 2016-02-12 2016-02-12
PCT/US2017/017295 WO2017139526A1 (en) 2016-02-12 2017-02-10 Tetrahydroisoquinoline derivatives

Publications (1)

Publication Number Publication Date
BR112018016475A2 true BR112018016475A2 (pt) 2018-12-26

Family

ID=59561239

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018016475A BR112018016475A2 (pt) 2016-02-12 2017-02-10 derivados de tetrahidroisoquinolina

Country Status (31)

Country Link
US (5) US9914741B2 (pt)
EP (2) EP4032877A1 (pt)
JP (2) JP6832943B2 (pt)
KR (1) KR20180120701A (pt)
CN (2) CN113666938A (pt)
AR (1) AR107592A1 (pt)
AU (1) AU2017217663B2 (pt)
BR (1) BR112018016475A2 (pt)
CA (1) CA3012839A1 (pt)
CL (1) CL2018002287A1 (pt)
CO (1) CO2018007920A2 (pt)
DK (1) DK3413892T3 (pt)
ES (1) ES2913423T3 (pt)
HR (1) HRP20220655T1 (pt)
HU (1) HUE058820T2 (pt)
IL (1) IL261055B (pt)
LT (1) LT3413892T (pt)
MA (1) MA44018B1 (pt)
MD (1) MD3413892T2 (pt)
MX (1) MX2018009759A (pt)
NZ (1) NZ746311A (pt)
PH (1) PH12018501694A1 (pt)
PL (1) PL3413892T3 (pt)
PT (1) PT3413892T (pt)
RS (1) RS63240B1 (pt)
RU (1) RU2743424C2 (pt)
SG (1) SG11201806416XA (pt)
SI (1) SI3413892T1 (pt)
TW (2) TWI719138B (pt)
UA (1) UA124879C2 (pt)
WO (1) WO2017139526A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113666938A (zh) 2016-02-12 2021-11-19 细胞动力学股份有限公司 四氢异喹啉衍生物
US11981644B2 (en) * 2020-11-06 2024-05-14 Cytokinetics, Inc. Bicyclic 1,4-diazepanones and therapeutic uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3301857A (en) 1963-08-26 1967-01-31 Hoffmann La Roche Spiro
SE368009B (pt) 1971-09-16 1974-06-17 Kabi Ab
CZ292806B6 (cs) * 1996-08-06 2003-12-17 Pfizer Inc. Pyrido- nebo pyrimido-6,6- nebo -6,7-bicyklické deriváty, farmaceutické kompozice na jejich bázi
CN1252054C (zh) 1996-09-25 2006-04-19 曾尼卡有限公司 抑制生长因子的作用的喹啉衍生物
US6410254B1 (en) 1999-05-18 2002-06-25 Cytokinetics Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US6743599B1 (en) 1999-05-18 2004-06-01 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
US7202051B1 (en) 1999-05-18 2007-04-10 Cytokinetics, Inc. Compositions and assays utilizing ADP or phosphate for detecting protein modulators
DE60024631T2 (de) * 1999-07-26 2006-06-14 Banyu Pharma Co Ltd Biaryl-harnstoff-derivate
JP2001106673A (ja) 1999-07-26 2001-04-17 Banyu Pharmaceut Co Ltd ビアリールウレア誘導体
GB0321538D0 (en) 2003-09-13 2003-10-15 Glaxo Group Ltd Therapeutically useful compounds
EP1740584B9 (en) * 2004-04-28 2010-06-09 Takeda Pharmaceutical Company Limited Fused quinoline derivative and use thereof
CA2631777A1 (en) * 2005-12-22 2007-07-05 Wyeth Substituted isoquinoline-1,3(2h,4h)-diones, 1-thioxo-1,4-dihydro-2h-isoquinoline-3-ones and 1,4-dihydro-3(2h)-isoquinolones and use thereof as kinase inhibitor
GB0613208D0 (en) 2006-07-03 2006-08-09 Glaxo Group Ltd Compounds
PT2069352E (pt) * 2006-08-02 2014-01-02 Cytokinetics Inc Certas entidades químicas, composições e métodos
JP5405314B2 (ja) * 2006-12-27 2014-02-05 サノフイ シクロアルキルアミン置換イソキノロン誘導体
AU2007339692B2 (en) 2007-01-05 2012-01-19 Daiichi Sankyo Company, Limited Fused substituted aminopyrrolidine derivative
US8163909B2 (en) 2007-05-25 2012-04-24 Amgen Inc. Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use
US8383629B2 (en) * 2008-02-27 2013-02-26 Vitae Pharmaceuticals, Inc. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1
CN101518971B (zh) * 2008-02-29 2012-07-18 E.I.内穆尔杜邦公司 聚酯叠层膜和使用该叠层膜的太阳能电池板
CA2742007C (en) 2008-10-29 2014-07-08 Deciphera Pharmaceuticals, Llc Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities
WO2010131145A1 (en) 2009-05-12 2010-11-18 Pfizer Limited Cyclobutenedione derivatives
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
EP2560488B1 (en) 2010-04-23 2015-10-28 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
JP5860042B2 (ja) 2010-06-16 2016-02-16 ヴァイティー ファーマシューティカルズ，インコーポレイテッド 置換５、６及び７員複素環、そのような化合物を含有する医薬及びそれらの使用
JP2014510055A (ja) 2011-02-18 2014-04-24 アラーガン インコーポレイテッド ホスホジエステラーゼ１０（ｐｄｅ１０ａ）阻害剤としての置換６，７−ジアルコキシ−３−イソキノリノール誘導体
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
HUP1100241A3 (en) * 2011-05-06 2013-12-30 Richter Gedeon Nyrt Oxetane substituted pyrimidones
SG10201701101YA (en) 2012-04-02 2017-04-27 Cytokinetics Inc Methods for improving diaphragm function
CN111840294A (zh) 2012-04-11 2020-10-30 赛特凯恩蒂克公司 改善对骨骼肌疲劳的抵抗力的方法
AR091699A1 (es) * 2012-07-10 2015-02-25 Astellas Pharma Inc Derivado de indol carboxamida
ES2906218T3 (es) 2014-04-29 2022-04-13 Cytokinetics Inc Métodos para reducir la disminución de la capacidad vital
WO2016039367A1 (ja) 2014-09-09 2016-03-17 アステラス製薬株式会社 尿失禁予防用及び／又は治療用新規医薬組成物
CN113666938A (zh) 2016-02-12 2021-11-19 细胞动力学股份有限公司 四氢异喹啉衍生物

Also Published As

Publication number Publication date
DK3413892T3 (da) 2022-05-23
CN109069498B (zh) 2021-08-17
PT3413892T (pt) 2022-05-30
HUE058820T2 (hu) 2022-09-28
CN113666938A (zh) 2021-11-19
US20180148458A1 (en) 2018-05-31
EP3413892B1 (en) 2022-04-20
CO2018007920A2 (es) 2018-12-14
US10259821B2 (en) 2019-04-16
PL3413892T3 (pl) 2022-06-13
US9914741B2 (en) 2018-03-13
AU2017217663A1 (en) 2018-10-04
IL261055A (en) 2018-10-31
JP6832943B2 (ja) 2021-02-24
RU2743424C2 (ru) 2021-02-18
US20230125280A1 (en) 2023-04-27
LT3413892T (lt) 2022-06-10
EP3413892A1 (en) 2018-12-19
EP3413892A4 (en) 2019-08-14
US10689393B2 (en) 2020-06-23
TWI719138B (zh) 2021-02-21
RS63240B1 (sr) 2022-06-30
CL2018002287A1 (es) 2019-01-04
WO2017139526A1 (en) 2017-08-17
MX2018009759A (es) 2018-11-29
RU2018130002A (ru) 2020-03-12
EP4032877A1 (en) 2022-07-27
US20200270266A1 (en) 2020-08-27
PH12018501694A1 (en) 2019-01-28
US20190194220A1 (en) 2019-06-27
MA44018B1 (fr) 2022-05-31
TW201741316A (zh) 2017-12-01
US11479561B2 (en) 2022-10-25
AU2017217663B2 (en) 2021-06-17
MD3413892T2 (ro) 2022-06-30
IL261055B (en) 2021-03-25
TW202138373A (zh) 2021-10-16
SI3413892T1 (sl) 2022-06-30
WO2017139526A8 (en) 2018-08-16
JP2019509267A (ja) 2019-04-04
JP2021073270A (ja) 2021-05-13
NZ746311A (en) 2022-08-26
US20170233402A1 (en) 2017-08-17
CA3012839A1 (en) 2017-08-17
UA124879C2 (uk) 2021-12-08
KR20180120701A (ko) 2018-11-06
MA44018A (fr) 2018-12-19
TWI773118B (zh) 2022-08-01
AR107592A1 (es) 2018-05-16
ES2913423T3 (es) 2022-06-02
HRP20220655T1 (hr) 2022-06-24
CN109069498A (zh) 2018-12-21
JP7137650B2 (ja) 2022-09-14
RU2018130002A3 (pt) 2020-03-24
SG11201806416XA (en) 2018-08-30

Similar Documents

Publication Publication Date Title
BR112022007627A2 (pt) Compostos moduladores do glp-1r
BR0317774A (pt) Uso de rimexolona no tratamento de olho seco
ATE524452T1 (de) Sulfonamide zur behandlung von kongestivem herzversagen, deren zusammensetzungen und verwendungen.
BR0008447A (pt) Métodos de tratamento de distúrbios mitocondriais
BR112018016475A2 (pt) derivados de tetrahidroisoquinolina
BRPI0416752A (pt) composição farmacêutica, uso de um ou mais compostos, método para a prevenção ou tratamento de distúrbios, compostos, e, processo para a preparação de uma composição farmacêutica
ECSP088430A (es) Diarilurea para el tratamiento de hipertensión pulmonar
BR112022009361A2 (pt) Novas lactonas funcionalizadas como moduladores do receptor 7 de 5- hidroxitriptamina e seu método de uso
BRPI0801078A2 (pt) processo para relaxar ou alisar os cabelos
BR112017012025A2 (pt) emulsões cosméticas
Wajsfisz et al. Surgical management of combined anterior or posterior cruciate ligament and posterolateral corner tears: for what functional results?
Rao et al. Pregait balance rehabilitation in acute stroke patients
BRPI0413939A (pt) creme para pentear o cabelo, método para tratar o cabelo e uso de uma composição para o cabelo
CY1110644T1 (el) 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις
MX2022011697A (es) Inhibidores de ciclofilina y usos de los mismos.
PL411499A1 (pl) Kompozycja farmaceutyczna i/lub kosmetyczna do leczenia chorób i uszkodzeń skóry, sposób wytwarzania kompozycji farmaceutycznej i/lub kosmetycznej oraz jej zastosowanie
EP3412276A3 (de) Zusammensetzung zur behandlung des trockenen auges
DE602004031964D1 (de) Ndlung von dermatologischen erkrankungen
BR112017018192A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica.
BR112022004563A2 (pt) Coliberação de sirna tgf-ß e sirna pdl1 para tratar câncer
BR112021021804A2 (pt) Composição farmacêutica para prevenção ou tratamento de miosite compreendendo mitocôndrias isoladas como ingrediente ativo
BR112021024644A2 (pt) Composições de lactobacillus e usos das mesmas
Cordasco Editorial Commentary: The Partial Thickness Rotator Cuff Tear: Is Acromioplasty Without Repair Ever Indicated?
BR112021026449A2 (pt) Composições e métodos que usam trigonelina e alto teor de proteína para evitar ou tratar condições ou distúrbios no músculo esquelético
Ahmad et al. Outcome of manipulation under anaesthesia in adhesive capsulitis patients

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B25A Requested transfer of rights approved

Owner name: CYTOKINETICS, INCORPORATED (US)

B25G Requested change of headquarter approved

Owner name: CYTOKINETICS, INCORPORATED (US)